You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 130 No. 4, April 1994 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Studies
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (41)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Zidovudine Improves Psoriasis in Human Immunodeficiency Virus—Positive Males

Madeleine Duvic, MD; Martin M. Crane, PhD; Marcus Conant, MD; Stephen E. Mahoney, MD; John D. Reveille, MD; Sandra Nusinoff Lehrman, MD

Arch Dermatol. 1994;130(4):447-451.


Abstract



Background and Design
Patients with human immunodeficiency virus (HIV) infection can develop severe psoriasis, which is difficult to treat using conventional therapy. Anecdotal case reports have suggested that administration of zidovudine can improve psoriasis in the HIV-infected patient. An open-label study was conducted to determine the safety and effectiveness of zidovudine therapy in 24 patients with HIV-associated psoriasis and to correlate response with laboratory and clinical variables.

Results
Of 19 evaluable patients, 90% had either par- tial (58%) or complete (32%) improvement of their HIVassociated psoriasis during zidovudine therapy. Greater than 75% reduction in the body surface area involved was positively associated with antigenemia and an age younger than 30 years.

Conclusions
Zidovudine therapy, at a dosage of 1200 mg/d, appears to be beneficial in the treatment of HIV-associated psoriasis, although long-term relapses occurred and the associated arthritis did not improve.

(Arch Dermatol. 1994;130:447-451)



Author Affiliations



From the Departments of Dermatology (Drs Duvic and Mahoney) and Internal Medicine (Drs Duvic and Reveille) and the Division of Rheumatology (Dr Reveille), University of Texas Medical School, Houston; the Division of Medicine, Section of Dermatology, M. D. Anderson Cancer Center, Houston, Tex (Dr Duvic); Epidemiology Discipline, School of Public Health, University of Texas Health Science Center, Houston (Dr Crane); the Department of Dermatology, University of California, San Francisco (Dr Conant); and the Department of Infectious Diseases, Burroughs Wellcome Co, Research Triangle Park, NC (Dr Nusinoff Lehrman). Dr Crane is now with the Division of Medical Education and Research, Greenville (SC) Hospital System.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Carbamazepine in Reiter's syndrome
Goyal et al.
Sex. Transm. Infect. 2000;76:220-220.
FULL TEXT  

Acitretin Therapy Is Effective for Psoriasis Associated With Human Immunodeficiency Virus Infection
Buccheri et al.
Arch Dermatol 1997;133:711-715.
ABSTRACT  

Dramatic Cutaneous Psoriasis Improvement in a Patient With the Human Immunodeficiency Virus Treated With 2',3'-Dideoxycytidine and Ritonavir
Berthelot et al.
Arch Dermatol 1997;133:531-531.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.